Flatlander schreef op 14 nov 2019 om 15:20:
Based on my quick read of the release, there were several pieces of good news.
40% of the new Idylla Console placements were in the U.S. -this suggests that the recently ramped up sales team is hitting the ground running and probably shows that Fisher did not market the product very hard, BCART has often mentioned that the lag between console placement and increased cartidge sales is about a half year. So we should expect to see this show up in next years cartridge sales.
The Nichirei Japan registration could be huge. The initial press release of the collaboration indicated that after the registration that Nichirei would roll the system out into their 2000 lab facilities. Since this occurred in October I will be looking forward to an update of this in March.
Onco Dx Breast is in validation and is still on track for EU approvals next year.
There were also some disappointments. No mention of Septicyte despite their partner Immunexpress saying that they expect approvals next year. Potentially they are leaving it up to their partner to take the lead on news releases but once its out there why not discuss it with shareholders?
There was also no mention of the Wonfu registration or collaboration status.
Based on these observations, I think BCART subscribes to the less is more adage. They provide minimal color other than the basic metrics the investor has been accustomed to. This can be a positive if the new product/geography inflection point comes (as I suspect) in late 2020 and they start exceeding their own estimates.